WeVote
Log In

Bill

Bill

SD 1910

An Act enhancing health care market oversight and pharmaceutical access

194th Legislature (2025-2026) Introduced by Jo Comerford and 2 co-sponsors

Massachusetts bill enhancing health care market oversight and pharmaceutical access to improve competition, drug affordability, and patient healthcare options.

House concurred
0
WeVote Research Nonpartisan
Bill Summary · SD 1910

Legislative bill overview

SD 1910 is a Massachusetts bill focused on strengthening regulatory oversight of health care markets and improving access to pharmaceuticals. The bill, introduced by representatives Comerford, Friedman, and Rausch, has been referred to the Health Care Financing Committee for review. The specific mechanisms and provisions are not detailed in the available information, but the title indicates it addresses market competition and drug accessibility issues.

Why is this important

Health care market oversight directly affects drug prices, insurance competition, and patient access to medications—issues that significantly impact household budgets and health outcomes. Massachusetts's approach could serve as a model for other states and potentially influence federal policy discussions on pharmaceutical regulation and health care competition.

Potential points of contention

  • Pharmaceutical industry resistance: Expanded oversight may face opposition from drug manufacturers concerned about price controls or increased regulatory burden
  • Insurance market regulation: Defining appropriate market controls without stifling competition or reducing insurer participation in the state market
  • Implementation costs: Government agencies would need resources to enforce enhanced oversight, potentially raising administrative expenses

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.